Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its therapeutic reach, and reinforce future growth prospects. Against a backdrop of evolving market dynamics and increasing competitive pressures, the company selectively pursued partnerships, acquisitions, and licensing agreements that add strategic depth without diluting focus.
A notable theme in 2025 was the company’s push into next-generation modalities and underserved therapeutic areas — aiming to diversify beyond current revenue drivers and position Novartis strongly for future demand.
One of the year’s headline transactions was the agreement to acquire Avidity Biosciences for approximately $12 billion in cash. This acquisition brings Novartis Avidity’s RNA-based Antibody Oligonucleotide Conjugates (AOC) platform and multiple late-stage programs focused on rare neuromuscular conditions — assets expected to unlock multi‑billion‑dollar opportunities and extend Novartis’ reach into precision RNA therapeutics at a time when genetic medicines are gaining traction.
Earlier in the year, Novartis advanced its cardiovascular strategy by agreeing to acquire Anthos Therapeutics, a clinical-stage company developing abelacimab, a potential first-in-class antibody for stroke prevention in patients with atrial fibrillation. The deal, anchored in late-stage development, aligns with broader efforts to deepen the company’s cardiovascular portfolio.
Expanding into rare disease and microRNA-based therapies, Novartis also launched a tender offer to acquire Regulus Therapeutics, a company focused on next-generation microRNA therapeutics. This adds early-stage innovation with potential to advance treatment of conditions such as autosomal dominant polycystic kidney disease (ADPKD), further diversifying the pipeline.
Beyond acquisitions, Novartis returned to Argo Biopharmaceutical with a multi-faceted cardiovascular collaboration worth up to $5 billion, securing rights to explore RNAi candidates and next-generation metabolic therapies. This strategic licensing deal underscores Novartis’ willingness to partner deeply when it accelerates access to emerging technology platforms.
And in immunology and allergy drug discovery, a significant partnership with UK-based Relation Therapeutics Ltd., valued at up to $1.7 billion, aims to leverage artificial intelligence and advanced human-data modeling to discover new targets for allergic disease therapies. This highlights Novartis’ commitment to bringing cutting-edge computational science into its discovery engine.
Strategic Impact and Outlook
Taken together, Novartis’ 2025 deals signal a shift toward platform-enabled science, high-impact therapeutic expansion, and technology integration. The Avidity acquisition, in particular, marks one of the company’s most ambitious bets in RNA therapeutics and neuromuscular disease, an area of significant unmet need and long-term growth potential. Anthos and Regulus add depth in cardiovascular and microRNA modalities, helping balance near-term performance with future innovation.
Strategic collaborations with Argo and Relation Therapeutics further emphasize Novartis’ preference for ecosystem engagement, accessing emerging science without overextension — a playbook designed for sustainable pipeline growth.
Looking ahead to 2026, these deals are expected to reinforce Novartis’ competitive position — broadening its platform capabilities and shaping a pipeline that can stand alongside the industry’s most innovative portfolios. If successfully integrated and advanced, the 2025 deal slate may accelerate scientific productivity, expand therapeutic reach, and support long-term value creation.
By